PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma

References

• Cathomas R, Lorch A, Bruins HM, Compérat EM, Cowan NC, Efstathiou JA, Fietkau R, Gakis G, Hernández V, Espinós EL, et al. The 2021 updated European Association of Urology guidelines on metastatic urothelial carcinoma. Eur Urol [Internet].2021 Nov [accessed 2021 Nov 8];S030228382102056X. https://linkinghub.elsevier.com/retrieve/pii/S030228382102056X
   Google Scholar
• Loriot Y, Matsubara N, Park SH, Huddart RA, Burgess EF, Houede N, Banek S, Laguerre B, Guadalupi V, Ku JH, et al. Phase 3 THOR study: results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt). JCO [Internet] 2023 Jun 10 [accessed 2023 Aug 18]];41(17_suppl):LBA4619–10. https://ascopubs.org/doi/10.1200/JCO.2023.41.17_suppl.LBA4619.
   Web of Science ®Google Scholar
• Balar AV, Castellano D, O’Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol [Internet]. 2017 Nov [accessed 2020 May 1]];18(11):1483–1492. 10.1016/S1470-2045(17)30616-2
   PubMed Web of Science ®Google Scholar
• Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet [Internet]. 2017 Jan [accessed 2020 May 1];389(10064):67–76. https://linkinghub.elsevier.com/retrieve/pii/S0140673616324552
   PubMed Web of Science ®Google Scholar
• Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol [Internet]. 2016 Dec [accessed 2019 Jul 12];17(12):e542–51. https://linkinghub.elsevier.com/retrieve/pii/S1470204516304065.
   PubMed Web of Science ®Google Scholar
• Eckstein M, Erben P, Kriegmair MC, Worst TS, Weiß CA, Wirtz RM, Wach S, Stoehr R, Sikic D, Geppert CI, et al. Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. Eur J Cancer. 2019;106:234–243. doi:10.1016/j.ejca.2018.11.007.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Mollica V, Massari F. Expression of programmed cell death ligand 1 as a predictive biomarker in metastatic urothelial carcinoma patients treated with first-line immune checkpoint inhibitors versus chemotherapy: a systematic review and meta-analysis. Eur Urol Focus. 2021 Jan 27;S2405-4569(21):00004–3.
   Google Scholar
• Eckstein M, Gupta S. New insights in predictive determinants of the tumor immune microenvironment for immune checkpoint inhibition: a never ending story? Ann Transl Med [Internet]. 2019 Jul [accessed 2020 May 1];7(S3).S135–S135. http://atm.amegroups.com/article/view/26472/24614.
   PubMedGoogle Scholar
• Eckstein M, Sikic D, Strissel PL, Erlmeier F. Evolution of PD-1 and PD-L1 gene and protein expression in primary tumors and corresponding liver metastases of metastatic bladder cancer. Eur Urol [Internet]. 2018 Oct [accessed 2021 Dec 10];74(4).527–529. https://linkinghub.elsevier.com/retrieve/pii/S0302283818304561.
   PubMed Web of Science ®Google Scholar
• Uhl B, Gevensleben H, Tolkach Y, Sailer V, Majores M, Jung M, Meller S, Stein J, Ellinger J, Dietrich D, et al. PITX2 DNA methylation as biomarker for individualized risk assessment of prostate cancer in core biopsies. J Mol Diagn. 2017;19(1):107–114. doi:10.1016/j.jmoldx.2016.08.008.
   PubMed Web of Science ®Google Scholar
• Dietrich D, Lesche R, Tetzner R, Krispin M, Dietrich J, Haedicke W, Schuster M, Kristiansen G. Analysis of DNA methylation of multiple genes in microdissected cells from formalin-fixed and paraffin-embedded tissues. J Histochem Cytochem. 2009 May;57(5):477–489. doi:10.1369/jhc.2009.953026.
   PubMed Web of Science ®Google Scholar
• Gevensleben H, Holmes EE, Goltz D, Dietrich J, Sailer V, Ellinger J, Dietrich D, Kristiansen G. PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. Oncotarget. 2016 Nov 29;7(48):79943–79955. doi:10.18632/oncotarget.13161.
   PubMedGoogle Scholar
• Franzen A, Vogt TJ, Müller T, Dietrich J, Schröck A, Golletz C, Brossart P, Bootz F, Landsberg J, Kristiansen G, et al. PD-L1 (CD274) and PD-L2 (PDCD1LG2) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas. Oncotarget. 2018 Jan 2;9(1):641–650. doi:10.18632/oncotarget.23080.
   PubMedGoogle Scholar
• Ralser DJ, Klümper N, Gevensleben H, Zarbl R, Kaiser C, Landsberg J, Hölzel M, Strieth S, Faridi A, Abramian A, et al. Molecular and immune correlates of PDCD1 (PD-1), PD-L1 (CD274), and PD-L2 (PDCD1LG2) DNA methylation in triple negative breast cancer. J Immunother (1991). 2021 Aug 4;44(8):319–324. doi:10.1097/CJI.0000000000000384.
   Web of Science ®Google Scholar
• Micevic G, Thakral D, McGeary M, Bosenberg MW. PD‐L1 methylation regulates PD‐L1 expression and is associated with melanoma survival. Pigment Cell Melanoma Res [Internet]. 2019 May [accessed 2022 Jan 4];32(3):435–440. 10.1111/pcmr.12745
   PubMed Web of Science ®Google Scholar
• Newell F, Pires da Silva I, Johansson PA, Menzies AM, Wilmott JS, Addala V, Carlino MS, Rizos H, Nones K, Edwards JJ, et al. Multiomic profiling of checkpoint inhibitor-treated melanoma: identifying predictors of response and resistance, and markers of biological discordance. Cancer Cell [Internet]. 2021 Dec [accessed 2021 Dec 28];40(1):S88–102.e7. https://linkinghub.elsevier.com/retrieve/pii/S1535610821006127.
   PubMed Web of Science ®Google Scholar
• Goltz D, Gevensleben H, Grünen S, Dietrich J, Kristiansen G, Landsberg J, Dietrich D. PD-L1 (CD274) promoter methylation predicts survival in patients with acute myeloid leukemia. Leukemia [Internet]. 2017 Mar [accessed 2019 Dec 30];31(3):738–743. http://www.nature.com/articles/leu2016328.
   PubMed Web of Science ®Google Scholar
• Goltz D, Gevensleben H, Dietrich J, Dietrich D. PD-L1 (CD274) promoter methylation predicts survival in colorectal cancer patients. Oncoimmunology. 2017;6(1):e1257454. doi:10.1080/2162402X.2016.1257454.
   PubMed Web of Science ®Google Scholar
• Klümper N, Ralser DJ, Zarbl R, Schlack K, Schrader AJ, Rehlinghaus M, Hoffmann MJ, Niegisch G, Uhlig A, Trojan L, et al. CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma. J Immunother Cancer. 2021 Aug;9(8):e002949. doi:10.1136/jitc-2021-002949.
   PubMed Web of Science ®Google Scholar
• Fietz S, Zarbl R, Niebel D, Posch C, Brossart P, Gielen GH, Strieth S, Pietsch T, Kristiansen G, Bootz F, et al. CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab). Cancer Immunol Immunother [Internet]. 2020 Nov 16 accessed 2020 Dec 29;70(6):1781–1788. http://link.springer.com/10.1007/s00262-020-02777-4.
   PubMed Web of Science ®Google Scholar
• Goltz D, Gevensleben H, Vogt TJ, Dietrich J, Golletz C, Bootz F, Kristiansen G, Landsberg J, Dietrich D. CTLA4 methylation predicts response to anti–PD-1 and anti–CTLA-4 immunotherapy in melanoma patients. JCI Insight [Internet]. accessed 2020 Jan 30;3(13). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124533/
   PubMed Web of Science ®Google Scholar
• Tully KH, Jütte H, Wirtz RM, Jarczyk J, Santiago-Walker A, Zengerling F, Breyer J, Sikic D, Kriegmair MC, von Hardenberg J, et al. Prognostic role of FGFR alterations and FGFR mRNA expression in metastatic urothelial cancer undergoing checkpoint Inhibitor therapy. Urology. 2021 Nov;157:93–101. doi:10.1016/j.urology.2021.05.055.
   PubMed Web of Science ®Google Scholar
• Pfannstiel C, Strissel PL, Chiappinelli KB, Sikic D, Wach S, Wirtz RM, Wullweber A, Taubert H, Breyer J, Otto W, et al. The tumor immune microenvironment drives a prognostic relevance that correlates with bladder cancer subtypes. Cancer Immunol Res. 2019;7(6):923–938. doi:10.1158/2326-6066.CIR-18-0758.
   PubMed Web of Science ®Google Scholar
• Sikic D, Weyerer V, Geppert CI, Bertz S, Lange F, Taubert H, Wach S, Schmitz-Draeger BJ, Wullich B, Hartmann A, et al. Utility of stromal tumor infiltrating lymphocyte scoring (sTils) for risk stratification of patients with muscle-invasive urothelial bladder cancer after radical cystectomy. Urol Oncol: Semin Orig Invest [Internet]. 2022 Feb accessed 2022 Sep 29;40(2):e63.19–e63.26. https://linkinghub.elsevier.com/retrieve/pii/S1078143921003434
   Web of Science ®Google Scholar
• Eckstein M, Strissel P, Strick R, Weyerer V, Wirtz R, Pfannstiel C, Wullweber A, Lange F, Erben P, Stoehr R, et al. Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy. J Immunother Cancer [Internet]. 2020 May [accessed 2022 Mar 2];8(1):e000162. https://jitc.bmj.com/lookup/doi/10.1136/jitc-2019-000162
   PubMed Web of Science ®Google Scholar
• Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, et al. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immunooncology biomarkers working group: part 1: assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further Research. Adv Anat Pathol. 2017 Sep;24(5):235–251. doi:10.1097/PAP.0000000000000162.
   PubMed Web of Science ®Google Scholar
• Weyerer V, Stoehr R, Bertz S, Lange F, Geppert CI, Wach S, Taubert H, Sikic D, Wullich B, Hartmann A, et al. Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort. World J Urol. 2021 Nov;39(11):4011–4019. doi:10.1007/s00345-021-03788-1.
   PubMed Web of Science ®Google Scholar
• Wullweber A, Strick R, Lange F, Sikic D, Taubert H, Wach S, Wullich B, Bertz S, Weyerer V, Stoehr R, et al. Bladder tumor subtype commitment occurs in carcinoma in situ driven by key signaling pathways including ECM remodeling. Cancer Research [Internet]. 2021 Mar 15 [accessed 2021 Oct 19];81(6):1552–1566. http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-5472.CAN-20-2336
   PubMed Web of Science ®Google Scholar
• Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol [Internet]. 2020 Apr [accessed 2020 May 1];77(4):420–433. https://linkinghub.elsevier.com/retrieve/pii/S0302283819306955
   PubMed Web of Science ®Google Scholar
• Dadhania V, Zhang M, Zhang L, Bondaruk J, Majewski T, Siefker-Radtke A, Guo CC, Dinney C, Cogdell DE, Zhang S, et al. Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use. EBioMedicine. 2016 Oct;12:105–117. doi:10.1016/j.ebiom.2016.08.036.
   PubMed Web of Science ®Google Scholar
• Casolino R, Johns AL, Courtot M, Lawlor RT, De Lorenzo F, Horgan D, Mateo J, Normanno N, Rubin M, Stein L, et al. Accelerating cancer omics and precision oncology in health care and research: a Lancet Oncology Commission. Lancet Oncol [Internet]. 2023 Feb [accessed 2023 Jan 31];24(2):123–125. https://linkinghub.elsevier.com/retrieve/pii/S1470204523000074
   PubMed Web of Science ®Google Scholar
• Wahida A, Buschhorn L, Fröhling S, Jost PJ, Schneeweiss A, Lichter P, Kurzrock R. The coming decade in precision oncology: six riddles. Nat Rev Cancer [Internet]. 2023 Jan [accessed 2023 Jan 14];23(1).43–54. https://www.nature.com/articles/s41568-022-00529-3.
   PubMed Web of Science ®Google Scholar
• Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, Wistuba II, Rimm DL, Tsao MS, Hirsch FR. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol [Internet]. 2021 Feb 12 [accessed 2021 Feb 16];18(6).345–362. http://www.nature.com/articles/s41571-021-00473-5.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, de Wit R, Fradet Y, Climent MA, Petrylak DP, Lee JL, Fong L, Necchi A, Sternberg CN, O’Donnell PH, et al. Putative biomarkers of clinical benefit with pembrolizumab in advanced urothelial cancer: results from the KEYNOTE-045 and KEYNOTE-052 landmark trials. Clin Cancer Res. 2022 May 13;28(10):2050–2060. doi:10.1158/1078-0432.CCR-21-3089.
   PubMed Web of Science ®Google Scholar
• Erlmeier F, Klümper N, Landgraf L, Strissel PL, Strick R, Sikic D, Taubert H, Wach S, Geppert CI, Bahlinger V, et al. Spatial immunephenotypes of distant metastases but not matched primary urothelial carcinomas predict response to immune checkpoint inhibition. Eur Urol [Internet]. 2022 Nov [accessed 2022 Nov 10];83(2):S133–142. https://linkinghub.elsevier.com/retrieve/pii/S0302283822027749.
   PubMed Web of Science ®Google Scholar
• Tejedor JR, Bueno C, Cobo I, Bayón GF, Prieto C, Mangas C, Pérez RF, Santamarina P, Urdinguio RG, Menéndez P, et al. Epigenome-wide analysis reveals specific DNA hypermethylation of T cells during human hematopoietic differentiation. Epigenomics. 2018 Jul;10(7):903–923. doi:10.2217/epi-2017-0163.
   PubMed Web of Science ®Google Scholar
• de Vos L, Grünwald I, Bawden EG, Dietrich J, Scheckenbach K, Wiek C, de Vos L, Zarbl R, Bootz F, Landsberg J, et al. The landscape of CD28, CD80, CD86, CTLA4, and ICOS DNA methylation in head and neck squamous cell carcinomas. Epigenetics. 2020 Nov;15(11):1195–1212. doi:10.1080/15592294.2020.1754675.
   PubMed Web of Science ®Google Scholar
• Hashimoto SI, Ogoshi K, Sasaki A, Abe J, Qu W, Nakatani Y, Ahsan B, Oshima K, Shand FH, Ametani A, et al. Coordinated changes in DNA methylation in antigen-specific memory CD4 T cells. J Immunol. 2013 Apr 15;190(8):4076–4091. doi:10.4049/jimmunol.1202267.
   PubMed Web of Science ®Google Scholar
• Durek P, Nordström K, Gasparoni G, Salhab A, Kressler C, de Almeida M, Bassler K, Ulas T, Schmidt F, Xiong J, et al. Epigenomic profiling of human CD4+ T cells supports a linear differentiation model and highlights molecular regulators of memory development. Immunity. 2016 Nov 15;45(5):1148–1161. doi:10.1016/j.immuni.2016.10.022.
   PubMed Web of Science ®Google Scholar
• Pauken KE, Sammons MA, Odorizzi PM, Manne S, Godec J, Khan O, Drake AM, Chen Z, Sen DR, Kurachi M, et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Sci. 2016 Dec 2;354(6316):1160–1165. doi:10.1126/science.aaf2807.
   PubMed Web of Science ®Google Scholar
• Sen DR, Kaminski J, Barnitz RA, Kurachi M, Gerdemann U, Yates KB, Tsao H-W, Godec J, LaFleur MW, Brown FD, et al. The epigenetic landscape of T cell exhaustion. Sci. 2016 Dec 2;354(6316):1165–1169. doi:10.1126/science.aae0491.
   PubMed Web of Science ®Google Scholar
• Ghoneim HE, Fan Y, Moustaki A, Abdelsamed HA, Dash P, Dogra P, Carter R, Awad W, Neale G, Thomas PG, et al. De Novo epigenetic programs Inhibit PD-1 blockade-mediated T cell rejuvenation. Cell. 2017 Jun 29;170(1):142–157.e19. doi:10.1016/j.cell.2017.06.007.
   PubMed Web of Science ®Google Scholar
• Huang RSP, Murugesan K, Montesion M, Pavlick DC, Mata DA, Hiemenz MC, Decker B, Frampton G, Albacker LA, Ross JS. Pan-cancer landscape of CD274 (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression. J Immunother Cancer [Internet]. 2021 May [accessed 2021 Aug 2];9(5):e002680. https://jitc.bmj.com/lookup/doi/10.1136/jitc-2021-002680
   PubMed Web of Science ®Google Scholar